Goodwin Procter·IP / PATENT

Takeda Sues Alvotech Over Vedolizumab Biosimilar

Takeda filed a BPCIA patent-infringement suit against Alvotech in New Jersey federal court, alleging the proposed biosimilar AVT16 infringes six patents for its biologic drug ENTYVIO®.

bpciabiosimilarspatent-infringementpharmatakedaalvotechvedolizumab

Read the original firm alert → Saturday, September 5, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.